Company: NDRA
Filing Date: 2025-10-17
Form Type: PRE 14A
Source: 0001654954-25-011931
Chunk: 32

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-17
Form: PRE 14A
Chunk 32
---
 Name                   |     | Fees Earned or Paid in Cash ($) |        |     | Option Awards ($)(1) |     |     | Total ($) |        |
| Anthony DiGiandomenico |     |                                 | 40,000 |     |                      | 954 |     |           | 40,954 |
| Michael Harsh          |     |                                 | 40,000 |     |                      | 954 |     |           | 40,954 |
| Louis Basenese         |     |                                 | 40,000 |     |                      | 954 |     |           | 40,954 |

| (1) | In January 2024, members of the Board were awarded their annual option grant to purchase 600 shares with a per share exercise price of $1.59. This grant was subject to adjustment due to the Company’s August 2024 Reverse Stock Split and the November 2024 Reverse Stock Split. After adjustment, this grant is for 0.3429 shares with a per share exercise price of $2,782.50. The amounts shown in this column indicate the grant date fair value of option awards granted in the subject year computed in accordance with FASB ASC Topic 718. For additional information regarding the assumptions made in calculating these amounts, see Notes 2 and 8 to the audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The following table shows the number of shares subject to outstanding option awards held by each non-employee director as of December 31, 2024: |

| 25 |

| Name                   |     | Shares Subject to Outstanding Option Awards |    |
| Louis Basenese         |     |                                             |  7 |
| Anthony DiGiandomenico |     |                                             | 11 |
| Michael Harsh          |     |                                             | 11 |

ENDRA Policy Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Non-Public Information

We have no practice or policy of coordinating or timing the release of Company information around the grant date of our equity incentive awards, and we have not timed the disclosure of material non-public information for the purpose of affecting the value of executive compensation. During fiscal 2024, we did not grant any stock options (or similar awards) to any of our named executive officers during any period beginning four business days before and ending one business day after the filing of any periodic